Nicholas T. Perry

Nicholas T. Perry

Auto-generated profile, based on publicly available information

Nicholas T. Perry

Arc Institute, Palo Alto, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Nature
Verified
Journal Article
Open access
PDF file
MDMatthew G. Durrant
Matthew G. Durrant
NPNicholas T. Perry
Nicholas T. Perry
JPJames J. Pai
James J. Pai
AJAditya R. Jangid
Aditya R. Jangid
JAJanuka S. Athukoralage
Januka S. Athukoralage
PHPatrick D. Hsu
Patrick D. Hsu
Genomic rearrangements, encompassing mutational changes in the genome such as insertions, deletions or inversions, are essential for genetic diversity. These rearrangements are typically orchestrated by enzymes that are involved in fundamental DNA repair processes, such as homologous recombination, or in the transposition of foreign genetic material by viruses and mobile genetic elements1,2. Here we report that IS110 insertion sequences, a family of minimal and autonomous mobile genetic elements, express a structured non-coding RNA that binds specifically to their encoded recombinase. This bridge RNA contains two internal loops encoding nucleotide stretches that base-pair with the target DNA and the donor DNA, which is the IS110 element itself. We demonstrate that the target-binding and donor-binding loops can be independently reprogrammed to direct sequence-specific recombination between two DNA molecules. This modularity enables the insertion of DNA into genomic target sites, as well as programmable DNA excision and inversion. The IS110 bridge recombination system expands the diversity of nucleic-acid-guided systems beyond CRISPR and RNA interference, offering a unified mechanism for the three fundamental DNA rearrangements—insertion, excision and inversion—that are required for genome design.

26 June 2024 in Nature
Verified
Journal Article
Open access
PDF file
MHMasahiro Hiraizumi
Masahiro Hiraizumi
NPNicholas T. Perry
Nicholas T. Perry
MDMatthew G. Durrant
Matthew G. Durrant
TSTeppei Soma
Teppei Soma
NNNaoto Nagahata
Naoto Nagahata
HNHiroshi Nishimasu
Hiroshi Nishimasu
Insertion sequence (IS) elements are the simplest autonomous transposable elements found in prokaryotic genomes1. We recently discovered that IS110 family elements encode a recombinase and a non-coding bridge RNA (bRNA) that confers modular specificity for target DNA and donor DNA through two programmable loops2. Here we report the cryo-electron microscopy structures of the IS110 recombinase in complex with its bRNA, target DNA and donor DNA in three different stages of the recombination reaction cycle. The IS110 synaptic complex comprises two recombinase dimers, one of which houses the target-binding loop of the bRNA and binds to target DNA, whereas the other coordinates the bRNA donor-binding loop and donor DNA. We uncovered the formation of a composite RuvC–Tnp active site that spans the two dimers, positioning the catalytic serine residues adjacent to the recombination sites in both target and donor DNA. A comparison of the three structures revealed that (1) the top strands of target and donor DNA are cleaved at the composite active sites to form covalent 5′-phosphoserine intermediates, (2) the cleaved DNA strands are exchanged and religated to create a Holliday junction intermediate, and (3) this intermediate is subsequently resolved by cleavage of the bottom strands. Overall, this study reveals the mechanism by which a bispecific RNA confers target and donor DNA specificity to IS110 recombinases for programmable DNA recombination.

5 August 2021 in Nature Methods
Verified
Journal Article
Closed access
PDF file
YTY. Esther Tak
Y. Esther Tak
JHJoy E. Horng
Joy E. Horng
NPNicholas T. Perry
Nicholas T. Perry
HSHayley T. Schultz
Hayley T. Schultz
SISowmya Iyer
Sowmya Iyer
JJJ. Keith Joung
J. Keith Joung

12 March 2026 in Science
Verified
Journal Article
Closed access
NPNicholas T. Perry
Nicholas T. Perry
LBLiam J. Bartie
Liam J. Bartie
DKDhruva Katrekar
Dhruva Katrekar
GGGabriel A. Gonzalez
Gabriel A. Gonzalez
MDMatthew G. Durrant
Matthew G. Durrant
PHPatrick D. Hsu
Patrick D. Hsu
Bridge recombinases are naturally occurring RNA-guided DNA recombinases that we previously demonstrated can programmably insert, excise, and invert DNA in vitro and in Escherichia coli . In this study, we report the discovery and engineering of the bridge recombinase ortholog ISCro4 for universal rearrangements of the human genome. We defined strategies for the optimal application of bridge systems, leveraging mechanistic insights to improve their targeting specificity. Through rational engineering of the ISCro4 bridge RNA and deep mutational scanning of its recombinase, we achieved up to 20% insertion efficiency into the human genome and genome-wide specificity as high as 82%. We further demonstrated intrachromosomal inversion and excision, mobilizing up to 0.93 megabases of DNA. Lastly, we provided proof of concept for plasmid-based excision of disease-relevant gene regulatory regions or repeat expansions.

15 January 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NPNicholas Perry
Nicholas Perry
KWKevin Wasko
Kevin Wasko
JCJason Cheng
Jason Cheng
DTDiana Tabbaa
Diana Tabbaa
EMEugenio Marco
Eugenio Marco
CBChristopher M. Borges
Christopher M. Borges
Human regulatory T cells (Tregs) have been implicated in cancer immunotherapy and are also an emerging cellular therapeutic for the treatment of multiple indications. Although Treg stability during ex vivo culture has improved, methods to assess Treg stability such as bisulfite Sanger sequencing to determine the methylation status of the Treg-specific demethylated region (TSDR) have remained unchanged. Bisulfite Sanger sequencing is not only costly and cumbersome to perform, it is inaccurate because of relatively low read counts. Bisulfite next-generation sequencing, although more accurate, is a less accessible method. In this study, we describe the application of methylation-sensitive restriction enzymes (MSRE) and quantitative PCR (qPCR) to determine the methylation status of the TSDR. Using known ratios of Tregs and non-Tregs, we show that MSRE-qPCR can distinguish the methylation status of the TSDR in populations of cells containing increasing proportions of Tregs from 0 to 100%. In a comparison with values obtained from an established bisulfite next-generation sequencing approach for determining the methylation status of the TSDR, our MSRE-qPCR results were within 5% on average for all samples with a high percentage (>70%) of Tregs, reinforcing that MSRE-qPCR can be completed in less time than other methods with the same level of accuracy. The value of this assay was further demonstrated by quantifying differences in TSDR methylation status of Tregs treated with and without rapamycin during an ex vivo expansion culture. Together, we show that our novel application of the MSRE-qPCR to the TSDR is an optimal assay for accurate assessment of Treg purity.

14 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
NPNicholas T. Perry
Nicholas T. Perry
LBLiam J. Bartie
Liam J. Bartie
DKDhruva Katrekar
Dhruva Katrekar
GGGabriel A. Gonzalez
Gabriel A. Gonzalez
MDMatthew G. Durrant
Matthew G. Durrant
PHPatrick D. Hsu
Patrick D. Hsu
Bridge recombinases are a class of naturally occurring RNA-guided DNA recombinases. We previously demonstrated they can programmably insert, excise, and invert DNA in vitro and in bacteria. Here, we report the discovery and engineering of IS622, a simple two-component system capable of universal DNA rearrangements of the human genome. We define strategies for the optimal application of bridge systems, leveraging mechanistic insights to improve their targeting specificity. Through rational engineering of the IS622 bridge RNA and deep mutational scanning of its recombinase, we achieve up to 20% insertion efficiency into the human genome and genome-wide specificity as high as 82%. We further demonstrate intra-chromosomal inversion and excision, mobilizing up to 0.93 megabases of DNA. Finally, we provide proof-of concept for excision of a gene regulatory region or expanded repeats relevant for the treatment of genetic diseases.